Molecular Monitoring of Chronic Myeloid Leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Molecular monitoring of minimal residual disease (MRD) is vital for managing chronic myeloid leukemia (CML).
• Tyrosine kinase inhibitor (TKI) therapy requires precise molecular tools for treatment decisions, including dosage adjustment and discontinuation.
• Current molecular tests like BCR-ABL1 transcript monitoring and kinase domain mutation analysis are key for effective CML management.

Purpose of the Study:

• To provide a detailed, step-by-step protocol for quantitative BCR-ABL1 transcript measurement using real-time quantitative PCR (qPCR).
• To outline the methodology for RNA to cDNA conversion and subsequent qPCR analysis.
• To standardize a gold-standard molecular monitoring method for CML patients.

Main Methods:

• RNA extraction from patient samples.
• Conversion of RNA to complementary DNA (cDNA) using reverse transcription.
• Real-time quantitative PCR (qPCR) for sensitive detection and quantification of BCR-ABL1 oncogene transcripts.

Main Results:

• The described qPCR protocol enables highly sensitive quantification of BCR-ABL1 transcripts.
• This method offers superior sensitivity compared to traditional techniques like karyotyping and FISH.
• The protocol is established for use in a major reference laboratory setting.

Conclusions:

• Real-time quantitative PCR (qPCR) is the gold-standard for monitoring BCR-ABL1 transcripts in CML patients.
• Accurate molecular monitoring using qPCR is essential for guiding TKI therapy and assessing treatment outcomes.
• Standardized protocols for qPCR are critical for reliable MRD assessment in CML.